A Nova Scotia-based company has received Health Canada approval to conduct a clinical trial to determine if psilocybin, a psychedelic compound found in magic mushrooms, can help those with PTSD who are treatment-resistant.
Halucenex Life Sciences Inc. in Windsor, N.S., is in the midst of the province's first clinical trial using the psychoactive substance psilocybin. Researchers hope to demonstrate the efficacy of the drug for treating post-traumatic stress disorder.
Company announces upcoming CEO change and potential changes to the Board of Directors.BOCA RATON, FL / ACCESSWIRE / October 7, 2022 / Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN)
Greenlane Announces Management Changes In Connection With Transition to Consumer Brands Business Model theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.